Rapid Delivery of Nanobodies/VHHs into Living Cells via Expressing In Vitro-Transcribed mRNA
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The mRNA delivery has a high potential in many fields and has been previously reported for several cell lines, such as fibroblasts, dendritic cells, macrophages and various stem cells [12,13,14,15].”
From The Prodigious Potential of mRNA Electrotransfer as a Substitute to Conventional DNA-Based Transient Transfection (2023) · cites this paper as [15]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
mRNA-based therapeutics--developing a new class of drugs
Sahin, U., Karikó, K., & Türeci, Ö. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4278 · Cited by 2,474 · cited 1×
“So the development of IVTmRNA-based therapeutics has gained broad attention.(14)One of themain uses of IVTmRNA is to deliver protein into living cells, but recently, nanobodies/VHHs have been expanded toward mining from traditional antibodies.”
BackgroundExpression of therapeutic proteins after delivery of chemically modified mRNA in mice
Kormann, M. S. D., Hasenpusch, G., Aneja, M. K., Nica, G., Flemmer, A. W., Herber-Jonat, S., Huppmann, M., Mays, L. E., Illenyi, M., Schams, A., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1733 · Cited by 733 · cited 3×
“In order to increase the stability of mRNA, there is an inclusion of chemically modified nucleotides.33 (1) Kormann et al.22 have shown that the replacement of only 25% of uridine and cytidine residues by 2-thiouridine and 5-methyl-cytidine suffices to increase mRNA stability, as well as to reduce the activation of in…”
BackgroundMethodInfluentialSharova, L. V., Sharov, A. A., Nedorezov, T., Piao, Y., Shaik, N., & Ko, M. S. H. (2009) · DNA Research · doi:10.1093/dnares/dsn030 · Cited by 591 · cited 1×
“Recently, data on mRNA half lives and the corresponding UTR sequences have been published.(37,38)”
BackgroundCell specific delivery of modified mRNA expressing therapeutic proteins to leukocytes
Veiga, N., Goldsmith, M., Granot, Y., Rosenblum, D., Dammes, N., Kedmi, R., Ramishetti, S., & Peer, D. (2018) · Nature Communications · doi:10.1038/s41467-018-06936-1 · Cited by 308 · cited 1×
“In addition, IVT mRNA-based therapeutics, unlike plasmids, do not need to be integrated into the genome and do not have a risk of insertional mutation of genomics.(32) For most pharmaceutical applications, it is also an advantage that IVT mRNA is only transiently active and completely degraded via metabolic pathways.”
BackgroundAn RNA toolbox for cancer immunotherapy
Pastor, F., Berraondo, P., Etxeberria, I., Frederick, J., Sahin, U., Gilboa, E., & Melero, I. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.132 · Cited by 229 · cited 1×
“Compared to intracellular delivery expressed by DNA, mRNA vaccines represent a promising alternative to conventional vaccine approaches due to their high potency, capacity for rapid development, as well as potency for low-cost manufacture and safe administration.(30,31) Plasmids need to be situated in the nucleus and…”
BackgroundSmall Molecule Targeted Recruitment of a Nuclease to RNA
Costales, M. G., Matsumoto, Y., Velagapudi, S. P., & Disney, M. D. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.8b01233 · Cited by 212 · cited 1×
“In vitro-transcribed (IVT) mRNA is an ideal carrier to deliver genetic information into living cells.(13) Over the last years, many interesting techniques of IVT mRNA were proposed and shown to be useful for many applications.”
BackgroundRNA binding protein/RNA element interactions and the control of translation
Pichon, X., A. Wilson, L., Stoneley, M., Bastide, A., A King, H., Somers, J., & E Willis, A. (2012) · Current Protein & Peptide Science · doi:10.2174/138920312801619475 · Cited by 144 · cited 1×
“It has been shown that a prolongation of the poly(A) tail to 120 nt has beneficial effects on protein expression, assumingly because of the protective effect of longer poly(A) tails; mRNAs with poly(A) tails shorter than 50 nt are claimed not to be translated at all.(20,34) (3) CappedmRNA can increase the translated e…”
Background
Research works printed but not linked: 35
- Strohl, 2018, Current progress in innovative engineered antibodies, Protein Cell, 9, 86, 10.1007/s13238-017-0457-8 · DOI · Paper page
- Leavy, 2010, Therapeutic antibodies: past, present and future, Nat. Rev. Immunol., 10, 297, 10.1038/nri2763 · DOI · Paper page
- Chan, 2010, Therapeutic antibodies for autoimmunity and inflammation, Nat. Rev. Immunol., 10, 301, 10.1038/nri2761 · DOI · Paper page
- Carter, 2018, Next generation antibody drugs: pursuit of the ‘high-hanging fruit’, Nat. Rev. Drug Discov., 17, 197, 10.1038/nrd.2017.227 · DOI · Paper page
- Trenevska, 2017, Therapeutic Antibodies against Intracellular Tumor Antigens, Front. Immunol., 8, 1001, 10.3389/fimmu.2017.01001 · DOI
- Marschall, 2011, Targeting antibodies to the cytoplasm, MAbs, 3, 3, 10.4161/mabs.3.1.14110 · DOI
- Stocks, 2005, Intrabodies as drug discovery tools and therapeutics, Curr. Opin. Chem. Biol., 9, 359, 10.1016/j.cbpa.2005.06.003 · DOI
- Muyldermans, 2001, Single domain camel antibodies: current status, J. Biotechnol., 74, 277
- Hamers-Casterman, 1993, Naturally occurring antibodies devoid of light chains, Nature, 363, 446, 10.1038/363446a0 · DOI · Paper page
- Zuo, 2017, Institute collection and analysis of Nanobodies (iCAN): a comprehensive database and analysis platform for nanobodies, BMC Genomics, 18, 797, 10.1186/s12864-017-4204-6 · DOI
- Leslie, 2018, Small but mighty, Science, 360, 594, 10.1126/science.360.6389.594 · DOI
- Rothbauer, 2006, Targeting and tracing antigens in live cells with fluorescent nanobodies, Nat. Methods, 3, 887, 10.1038/nmeth953 · DOI · Paper page
- Kubala, 2010, Structural and thermodynamic analysis of the GFP:GFP-nanobody complex, Protein Sci., 19, 2389, 10.1002/pro.519 · DOI · Paper page
- Maier, 2015, Real-time analysis of epithelial-mesenchymal transition using fluorescent single-domain antibodies, Sci. Rep., 5, 13402, 10.1038/srep13402 · DOI
- Herrmann, 2007, Intermediate filaments: from cell architecture to nanomechanics, Nat. Rev. Mol. Cell Biol., 8, 562, 10.1038/nrm2197 · DOI · Paper page
- Kawaguchi, 2003, The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress, Cell, 115, 727, 10.1016/S0092-8674(03)00939-5 · DOI · Paper page
- Johnston, 1998, Aggresomes: a cellular response to misfolded proteins, J. Cell Biol., 143, 1883, 10.1083/jcb.143.7.1883 · DOI · Paper page
- Moore, 2005, From birth to death: the complex lives of eukaryotic mRNAs, Science, 309, 1514, 10.1126/science.1111443 · DOI · Paper page
- Mignone, 2005, UTRdb and UTRsite: a collection of sequences and regulatory motifs of the untranslated regions of eukaryotic mRNAs, Nucleic Acids Res., 33, D141, 10.1093/nar/gki021 · DOI · Paper page
- Cheever, 2009, The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research, Clin. Cancer Res., 15, 5323, 10.1158/1078-0432.CCR-09-0737 · DOI · Paper page
- Freund, 2013, Targeting endogenous nuclear antigens by electrotransfer of monoclonal antibodies in living cells, MAbs, 5, 518, 10.4161/mabs.25084 · DOI
- Kimura, 2015, Visualizing posttranslational and epigenetic modifications of endogenous proteins in vivo, Histochem. Cell Biol., 144, 101, 10.1007/s00418-015-1344-0 · DOI
- Prochiantz, 2000, Messenger proteins: homeoproteins, TAT and others, Curr. Opin. Cell Biol., 12, 400, 10.1016/S0955-0674(00)00108-3 · DOI · Paper page
- Sánchez-Navarro, 2017, Cytosolic delivery: Just passing through, Nat. Chem., 9, 727, 10.1038/nchem.2837 · DOI
- Dinca, 2016, Intracellular Delivery of Proteins with Cell-Penetrating Peptides for Therapeutic Uses in Human Disease, Int. J. Mol. Sci., 17, 263, 10.3390/ijms17020263 · DOI · Paper page
- Kristensen, 2016, Applications and Challenges for Use of Cell-Penetrating Peptides as Delivery Vectors for Peptide and Protein Cargos, Int. J. Mol. Sci., 17, 185, 10.3390/ijms17020185 · DOI · Paper page
- Pardi, 2018, mRNA vaccines - a new era in vaccinology, Nat. Rev. Drug Discov., 17, 261, 10.1038/nrd.2017.243 · DOI · Paper page
- Karikó, 2007, Naturally occurring nucleoside modifications suppress the immunostimulatory activity of RNA: implication for therapeutic RNA development, Curr. Opin. Drug Discov. Devel., 10, 523
- Pesole, 2000, The untranslated regions of eukaryotic mRNAs: structure, function, evolution and bioinformatic tools for their analysis, Brief. Bioinform., 1, 236, 10.1093/bib/1.3.236 · DOI · Paper page
- Barrett, 2012, Regulation of eukaryotic gene expression by the untranslated gene regions and other non-coding elements, Cell. Mol. Life Sci., 69, 3613, 10.1007/s00018-012-0990-9 · DOI · Paper page
- ’t Hoen, 2011, mRNA degradation controls differentiation state-dependent differences in transcript and splice variant abundance, Nucleic Acids Res., 39, 556, 10.1093/nar/gkq790 · DOI · Paper page
- Peyvandi, 2016, Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura, N. Engl. J. Med., 374, 2497, 10.1056/NEJMoa1505533 · DOI · Paper page
- Zhang, 2017, Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade, Cell Discov., 3, 17004, 10.1038/celldisc.2017.4 · DOI · Paper page
- Riedl, 2008, Lifeact: a versatile marker to visualize F-actin, Nat. Methods, 5, 605, 10.1038/nmeth.1220 · DOI · Paper page
- Storrie, 1998, Recycling of golgi-resident glycosyltransferases through the ER reveals a novel pathway and provides an explanation for nocodazole-induced Golgi scattering, J. Cell Biol., 143, 1505, 10.1083/jcb.143.6.1505 · DOI · Paper page
Cited by
mRNA-based therapeutics: powerful and versatile tools to combat diseases
Qin, S., Tang, X., Chen, Y., Chen, K., Fan, N., Xiao, W., Zheng, Q., Li, G., Teng, Y., Wu, M., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01007-w · Cited by 771
Juncker, T., Chatton, B., & Donzeau, M. (2023) · Cells · doi:10.3390/cells12121591 · Cited by 6
Metadata
- Authors
- Zhou, X., Hao, R., Chen, C., Su, Z., Zhao, L., Luo, Z., & Xie, W.
- Venue
- Molecular Therapy - Methods & Clinical Development
- Publisher
- Elsevier BV
- Published
- 2020-06
- Volume
- 17
- Pages
- 401-408
- ISSN
- 2329-0501
- Cited by
- 26
- References
- 7
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
- Funders
- National Natural Science Foundation of China (81570743, 81303019)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.